Evidence map›Paper›PMID 24390604›Full record

ArticleJapanese journal of ophthalmology2014

Incidence of deepening of the upper eyelid sulcus on treatment with a tafluprost ophthalmic solution.

Rei Sakata, Shiroaki Shirato, Kazunori Miyata, Makoto Aihara

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Japanese journal of ophthalmology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07074782 (Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues), which is not on this map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07074782 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues: NEUROPA - a Retrospective Cohort Study

TypeobservationalSponsorAssociation for Innovation and Biomedical Research on Light and ImageRan2026 to 2026Enrolled1,500ConditionsGlaucoma
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 42 citations in OpenAlex.

  1. Impact of prostaglandin-associated periorbitopathy on surgical outcomes of trabeculectomy and ahmed glaucoma valve implantation.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Prostanoid receptor agonists for glaucoma treatment.Japanese journal of ophthalmology · 2021
    Review
  9. Observational
  10. Observational
  11. Article
  12. Article
  13. Review
  14. Prostaglandin-associated periorbitopathy.Indian journal of ophthalmology · 2016
    Article
  15. Article
  16. Prostaglandin-associated periorbitopathy in latanoprost users.Clinical ophthalmology (Auckland, N.Z.) · 2015
    Article
  17. Article
  18. In vivo (Athens, Greece)
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Rei SakataDepartment of Ophthalmology, Tokyo Metropolitan Geriatric Hospital, University of Tokyo, 35-2, Sakaecho, Itabashi, Tokyo, 173-0015, Japan, reisakata-tky@umin.ac.jp.
Shiroaki Shirato
Kazunori Miyata
Makoto Aihara
Miyata Eye Hospital · JPTokyo Metropolitan Geriatric Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDeepening of the upper eyelid sulcus (DUES), one symptom of prostaglandin-associated periorbitopathy, was recently found to be an additional side effect of prostaglandin-related ophthalmic solutions. Here, we prospectively investigated the incidence and factors associated with DUES in Japanese open-angle glaucoma patients initially treated with benzalkonium chloride (BAK)-preserved tafluprost (TAF).

methodsIn this open-label prospective study instilling TAF in one eye, mean deviation (MD) and intraocular pressure (IOP) were measured, and facial photographs and subjective reports of DUES were obtained at intervals over 6 months. Three ophthalmologists independently assessed the photographs of DUES and reached consensus. Relationships between demographic and ocular/systemic factors (age, sex, MD, refraction and IOP reduction) and DUES occurrence were evaluated.

resultsForty-three eyes of 43 glaucoma patients (24 men and 19 women) were evaluated. Mean IOP before treatment was 16.6 ± 2.7 and after treatment, 14.1 ± 2.3 mmHg (P < 0.001). The objective rate of DUES was 9 % (4/43) at 2 months, 14 % (6/43) at 4 months and 14 % (6/43) at 6 months. During this period, only one patient self-reported an occurrence of DUES. No significant association was found between DUES occurrence and any of the demographic, ocular, or systemic factors.

conclusionsPhysicians should inform patients about DUES as a minor side effect when prescribing TAF for IOP control.

Indexed as

Antihypertensive AgentsEyelid DiseasesFemaleGlaucoma, Open-AngleHumansIncidenceIntraocular PressureLow Tension GlaucomaMaleMiddle AgedOphthalmic SolutionsOrbital DiseasesPreservatives, PharmaceuticalProspective StudiesProstaglandins FAntihypertensive AgentsOphthalmic SolutionsPreservatives, PharmaceuticalProstaglandins Ftafluprost

Identifiers

PMID24390604
OpenAlexW2121182204

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.